Loading...
XNAS
PBYI
Market cap267mUSD
Dec 05, Last price  
5.30USD
1D
0.19%
1Q
5.37%
Jan 2017
-82.74%
IPO
-59.23%
Name

Puma Biotechnology Inc

Chart & Performance

D1W1MN
XNAS:PBYI chart
P/E
8.82
P/S
1.16
EPS
0.60
Div Yield, %
—
Shrs. gr., 5y
4.84%
Rev. gr., 5y
-3.28%
Revenues
230m
-2.19%
0000-281,0960000027,700,000251,000,000272,300,000225,100,000253,200,000228,000,000235,637,000230,468,000
Net income
30m
+40.23%
-15,093,000-14,083-16,836-15,976-10,232,878-74,300,000-54,659,000-142,000,000-239,300,000-276,000,000-292,000,000-113,600,000-82,723,000-60,000,000-29,100,000912,00021,591,00030,278,000
CFO
39m
+44.09%
-15,093,000-11,834-16,815-18,246-1,825,018-44,000,000-55,048,000-77,200,000-154,500,000-141,700,000-172,500,000-24,100,00022,400,000800,00020,700,000-15,800,00027,009,00038,918,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
URL
https://www.pumabiotechnology.com/
IPO date
Mar 21, 2012
Employees
192
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT